home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Sapphire Collection
/
Software Vault (Sapphire Collection) (Digital Impact).ISO
/
cdr16
/
med9410e.zip
/
M94B0795.TXT
< prev
next >
Wrap
Text File
|
1994-11-11
|
2KB
|
35 lines
Document 0795
DOCN M94B0795
TI Liposome encapsulated doxorubicin for the treatment of AIDS-associated
Kaposi's sarcoma (Meeting abstract).
DT 9412
AU Harrison M; Coker R; Tomlinson D; Stewart S; Dept. of Oncology, St
Mary's Hosp., London W2 1NY, UK
SO Proc Annu Meet Am Assoc Cancer Res; 35:A1139 1994. Unique Identifier :
AIDSLINE ICDB/94602825
AB Severe KS requiring chemotherapy affects 20-30% of patients with AIDS.
Doxorubicin within a polyethylene glycol containing liposome (Doxil,
LTI) has been used in a phase 2 study on 34 patients with severe KS. The
liposome is 90 nm in diameter and is composed of 20% cholesterol, 20%
polyethylene glycol, and 60% phosphatidyl choline. Polyethylene glycol
within the lipid membrane decreases uptake by the reticuloendothelial
system resulting in a half-life of 33-43 hours. A dose of 20 mg/m2 of
doxorubicin was given 2-3 times weekly on an outpatient basis via
peripheral venous access. A total number of 138 treatments were given,
the maximum for any single patient was 20. A response rate of 76% was
observed with 2 (6%) CR and 24 (70%) PR. Toxicity was mild, 3 patients
(9%) developed WHO grade I alopecia and 6 patients (18%) WHO grade I
nausea and vomiting. Antiemetics were not routinely given and not all
these episodes of nausea were attributed to Doxil. Quality of life
assessments showed that Doxil to be well tolerated with minimal
interruption in the patients lifestyle.
DE Acquired Immunodeficiency Syndrome/BLOOD/*DRUG THERAPY
Doxorubicin/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ PHARMACOKINETICS
Drug Carriers Human Liposomes Metabolic Clearance Rate/PHYSIOLOGY
Sarcoma, Kaposi's/BLOOD/*DRUG THERAPY Skin Neoplasms/BLOOD/*DRUG
THERAPY MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).